Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
RIGGS RORY B | Director | Jan 04 '24 | Sale | 27.55 | 35,702 | 983,504 | 20,099 | Jan 04 05:16 PM | RIGGS RORY B | Director | Jan 03 '24 | Sale | 27.79 | 199,098 | 5,532,276 | 55,801 | Jan 04 05:16 PM | RIGGS RORY B | Director | Jan 02 '24 | Sale | 28.52 | 235,200 | 6,707,081 | 254,899 | Jan 04 05:16 PM | Avara Management Ltd | 10% Owner | Dec 29 '23 | Sale | 28.04 | 65,803 | 1,845,406 | 2,477,520 | Jan 03 04:31 PM | Avara Management Ltd | 10% Owner | Dec 28 '23 | Sale | 28.20 | 209,863 | 5,918,934 | 2,543,323 | Dec 29 04:29 PM | Avara Management Ltd | 10% Owner | Dec 27 '23 | Sale | 28.01 | 41,729 | 1,168,754 | 2,753,186 | Dec 29 04:29 PM | Avara Management Ltd | 10% Owner | Dec 15 '23 | Sale | 28.01 | 10,229 | 286,499 | 2,794,915 | Dec 19 04:30 PM | Avara Management Ltd | 10% Owner | Dec 14 '23 | Sale | 28.91 | 364,441 | 10,534,276 | 2,805,144 | Dec 15 04:31 PM | Avara Management Ltd | 10% Owner | Dec 13 '23 | Sale | 28.95 | 307,935 | 8,916,012 | 3,169,585 | Dec 15 04:31 PM | Coyne Terrance P. | EVP & CFO | Aug 10 '23 | Sale | 30.75 | 37,500 | 1,153,091 | 790,000 | Aug 11 05:00 PM | Coyne Terrance P. | EVP & CFO | Aug 09 '23 | Sale | 30.72 | 37,500 | 1,151,936 | 827,500 | Aug 11 05:00 PM | Coyne Terrance P. | EVP & CFO | Jul 13 '23 | Sale | 30.93 | 37,500 | 1,159,958 | 865,000 | Jul 14 06:09 PM | Coyne Terrance P. | EVP & CFO | Jul 12 '23 | Sale | 31.07 | 37,500 | 1,165,256 | 902,500 | Jul 14 06:09 PM | Legorreta Pablo G. | CEO, Chairman of the Board | Jun 28 '23 | Buy | 29.51 | 130,000 | 3,836,768 | 600,000 | Jun 28 04:01 PM | Legorreta Pablo G. | CEO, Chairman of the Board | Jun 13 '23 | Buy | 32.78 | 45,000 | 1,474,902 | 470,000 | Jun 13 04:01 PM | Legorreta Pablo G. | CEO, Chairman of the Board | Jun 12 '23 | Buy | 33.00 | 45,000 | 1,484,946 | 425,000 | Jun 13 04:01 PM | Lloyd George W. | EVP, Investments & CLO | Jun 06 '23 | Sale | 33.82 | 79,099 | 2,674,796 | 30,000 | Jun 06 05:07 PM |
|